...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumori. >High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin's lymphoma in the rituximab era
【24h】

High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin's lymphoma in the rituximab era

机译：利妥昔单抗时代滤泡性非霍奇金淋巴瘤患者的大剂量化疗及自体异体造血干细胞移植

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

High-dose chemotherapy in lymphomas, and mainly non-Hodgkin's lymphomas, has been advancing since the 1970s. This therapeutic strategy is based on the supposed existence of a dose-response curve for cytotoxic agents. However, the available data are contradictory, so high-dose chemotherapy cannot be guaranteed as consolidation treatment for first-remission follicular lymphoma or diffuse large cell lymphoma. The objective of this paper is to review the current knowledge about high-dose chemotherapy followed by hematopoietic stem cell transplantation in follicular non-Hodgkin's lymphoma. The published studies on follicular lymphoma after first remission, recurrent follicular lymphoma, and transformed follicular lymphoma were assessed together with the data available on diffuse large cell lymphoma. During analysis of the studies, difficulties were encountered in comparing studies due to the heterogeneous nature of the data. High-dose chemotherapy as consolidation treatment after first remission or in recurrent or refractory disease was also analyzed.
机译：自1970年代以来，针对淋巴瘤（主要是非霍奇金淋巴瘤）的大剂量化疗一直在发展。该治疗策略基于细胞毒性剂的剂量反应曲线的假定存在。但是，现有数据相互矛盾，因此不能保证大剂量化疗可以作为合并治疗初次缓解的滤泡性淋巴瘤或弥漫性大细胞淋巴瘤。本文的目的是回顾当前有关大剂量化疗后滤泡性非霍奇金淋巴瘤造血干细胞移植的知识。评估了首次缓解后的滤泡性淋巴瘤，复发性滤泡性淋巴瘤和转化的滤泡性淋巴瘤的已发表研究，以及弥散性大细胞淋巴瘤的可用数据。在研究分析期间，由于数据的异质性，在比较研究时遇到了困难。还分析了首次缓解后或复发或难治性疾病中作为巩固治疗的大剂量化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号